Jennison Associates Has Boosted Reliance Steel & Aluminum Co (RS) Stake; 19 Analysts Bullish Jazz Pharmaceuticals plc (JAZZ)

June 20, 2018 - By Adrian Mccoy

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Jennison Associates Llc increased Reliance Steel & Aluminum Co (RS) stake by 182.89% reported in 2018Q1 SEC filing. Jennison Associates Llc acquired 341,024 shares as Reliance Steel & Aluminum Co (RS)’s stock declined 0.45%. The Jennison Associates Llc holds 527,492 shares with $45.23M value, up from 186,468 last quarter. Reliance Steel & Aluminum Co now has $6.65 billion valuation. The stock decreased 0.07% or $0.065 during the last trading session, reaching $91.895. About 33,533 shares traded. Reliance Steel & Aluminum Co. (NYSE:RS) has risen 26.96% since June 20, 2017 and is uptrending. It has outperformed by 14.39% the S&P500. Some Historical RS News: ; 26/04/2018 – Reliance Steel 1Q EPS $2.30; 27/04/2018 – RELIANCE STEEL & ALUMINUM CO RS.N : DEUTSCHE BANK RAISES TARGET PRICE TO $100 FROM $98; 16/03/2018 – Reliance Steel May Face Pressure, Industry Slowest in 16 Months; 26/04/2018 – Reliance Steel 1Q Net $169M; 26/04/2018 – Reliance Steel 1Q Adj EPS $2.30; 26/04/2018 – RELIANCE STEEL & ALUMINUM CO – “AEROSPACE DEMAND REMAINS STRONG, AND CONTINUES TO BE ONE OF COMPANY’S TOP-PERFORMING END MARKETS”; 05/03/2018 – Dir Sharkey III Gifts 500 Of Reliance Steel & Aluminum Co; 04/05/2018 – Report: Exploring Fundamental Drivers Behind Reliance Steel & Aluminum, Goldman Sachs BDC, IBERIABANK, Federal Signal, United T; 26/04/2018 – Reliance Steel Sees 2Q EPS $2.60-EPS $2.70; 19/04/2018 – DJ Reliance Steel & Aluminum Co, Inst Holders, 1Q 2018 (RS)

Among 23 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 19 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Jazz Pharmaceuticals had 85 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Friday, June 1 by RBC Capital Markets. Mizuho maintained it with “Neutral” rating and $124 target in Wednesday, February 24 report. The company was maintained on Monday, October 23 by Cowen & Co. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Sunday, December 3 by Cantor Fitzgerald. On Monday, August 7 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm earned “Buy” rating on Tuesday, September 19 by BMO Capital Markets. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has “Buy” rating given on Wednesday, November 8 by UBS. The stock has “Neutral” rating by Mizuho on Thursday, April 6. The rating was maintained by FBR Capital with “Buy” on Thursday, May 10. The firm has “Buy” rating given on Monday, July 17 by Deutsche Bank. See Jazz Pharmaceuticals plc (NASDAQ:JAZZ) latest ratings:

01/06/2018 Broker: RBC Capital Markets Rating: Buy New Target: $194.0000 Maintain
10/05/2018 Broker: FBR Capital Old Rating: Buy New Rating: Buy Old Target: $206 New Target: $211 Maintain
09/05/2018 Broker: BMO Capital Markets Old Rating: Outperform New Rating: Outperform Old Target: $199 New Target: $201 Maintain
07/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $202.0000 Maintain
30/04/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $202.0000 Maintain
12/04/2018 Broker: Piper Jaffray Rating: Buy New Target: $201.0000 Maintain
06/04/2018 Broker: Seaport Global Rating: Buy New Target: $175.0000 Maintain
23/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $160.0000 Maintain
19/03/2018 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight Upgrade
16/03/2018 Broker: Leerink Swann Rating: Buy New Target: $180.0 Maintain

Jennison Associates Llc decreased Anixter Intl Inc (NYSE:AXE) stake by 8,716 shares to 761,850 valued at $57.71M in 2018Q1. It also reduced Allergan Plc stake by 156,888 shares and now owns 1.94M shares. Steel Dynamics Inc (NASDAQ:STLD) was reduced too.

Investors sentiment decreased to 1.04 in 2018 Q1. Its down 0.03, from 1.07 in 2017Q4. It turned negative, as 23 investors sold RS shares while 111 reduced holdings. 49 funds opened positions while 91 raised stakes. 57.31 million shares or 2.17% less from 58.59 million shares in 2017Q4 were reported. Profund Advisors accumulated 10,541 shares. Aperio Group Lc owns 33,362 shares. Pillar Pacific Cap Mngmt Lc accumulated 3,705 shares. Grantham Mayo Van Otterloo Co Ltd Llc accumulated 45,540 shares or 0.02% of the stock. World Asset Mngmt accumulated 4,444 shares or 0.02% of the stock. Aqr Capital Mngmt, Connecticut-based fund reported 497,849 shares. Huntington Savings Bank holds 0% or 318 shares. Regentatlantic Ltd Liability Corporation has 24,779 shares for 0.18% of their portfolio. Pnc Fincl Svcs Group Inc Incorporated accumulated 9,412 shares. James Invest has invested 0.08% in Reliance Steel & Aluminum Co. (NYSE:RS). L & S Advisors Inc has 0.08% invested in Reliance Steel & Aluminum Co. (NYSE:RS) for 5,056 shares. Cullen Frost Bankers reported 0.01% of its portfolio in Reliance Steel & Aluminum Co. (NYSE:RS). Barrow Hanley Mewhinney & Strauss Limited Com invested in 1,395 shares or 0% of the stock. Oakbrook Limited Liability Com has invested 0.04% in Reliance Steel & Aluminum Co. (NYSE:RS). M&T Fincl Bank Corporation holds 0% or 4,504 shares in its portfolio.

Since February 20, 2018, it had 0 buys, and 10 sales for $8.21 million activity. 6,000 shares were sold by GIMBEL THOMAS W, worth $553,860 on Wednesday, February 28. KAMINSKI MARK V sold $786,216 worth of stock or 8,200 shares. 12,645 shares valued at $1.21 million were sold by Koch Stephen Paul on Friday, May 18. On Tuesday, March 6 MOLLINS GREGG J sold $2.82 million worth of Reliance Steel & Aluminum Co. (NYSE:RS) or 30,332 shares. 4,069 shares were sold by Shanley Michael Patrick, worth $392,659 on Wednesday, June 6. Another trade for 5,000 shares valued at $461,500 was made by HOFFMAN JAMES DONALD on Wednesday, February 21. HAYES DOUGLAS M sold $561,480 worth of stock.

Among 10 analysts covering Reliance Steel (NYSE:RS), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Reliance Steel had 41 analyst reports since September 8, 2015 according to SRatingsIntel. On Tuesday, October 20 the stock rating was initiated by Deutsche Bank with “Buy”. As per Tuesday, January 9, the company rating was maintained by Jefferies. The rating was downgraded by Bank of America on Friday, February 19 to “Neutral”. Deutsche Bank downgraded the stock to “Hold” rating in Wednesday, March 23 report. The company was maintained on Friday, November 3 by Cowen & Co. The rating was maintained by Deutsche Bank with “Buy” on Monday, December 5. KeyBanc Capital Markets maintained it with “Buy” rating and $95.0 target in Wednesday, January 10 report. As per Monday, January 9, the company rating was upgraded by KeyBanc Capital Markets. The stock of Reliance Steel & Aluminum Co. (NYSE:RS) has “Buy” rating given on Thursday, August 31 by Cowen & Co. The stock of Reliance Steel & Aluminum Co. (NYSE:RS) earned “Buy” rating by Bank of America on Tuesday, May 23.

More recent Reliance Steel & Aluminum Co. (NYSE:RS) news were published by: 247Wallst.com which released: “If Tariffs Are So Bad Why Are Steel Stocks Still Red Hot?” on June 12, 2018. Also Benzinga.com published the news titled: “KeyBanc Urges ‘Selective Bias’ On Carbon Steel Stocks” on June 14, 2018. Globenewswire.com‘s news article titled: “Reliance Steel & Aluminum Co. to Present at Deutsche Bank’s 9th Annual Global Industrials and Materials Summit” with publication date: June 01, 2018 was also an interesting one.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $10.90 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 24.89 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Investors sentiment decreased to 1.02 in 2018 Q1. Its down 0.07, from 1.09 in 2017Q4. It fall, as 29 investors sold Jazz Pharmaceuticals plc shares while 96 reduced holdings. 44 funds opened positions while 84 raised stakes. 51.95 million shares or 1.94% less from 52.98 million shares in 2017Q4 were reported. Mirae Asset Invs Communication Ltd accumulated 27,301 shares. Reilly Ltd Liability Corporation reported 23 shares. Ranger Inv Mgmt Limited Partnership holds 2,134 shares. Macquarie Grp holds 0% or 1,700 shares in its portfolio. Gratry Com Llc holds 6,763 shares or 1.41% of its portfolio. 120,209 are owned by Aqr Cap Mngmt Ltd Liability Corp. Brighton Jones Llc reported 0.03% stake. Meritage Portfolio Mngmt has invested 0.49% in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). X Communications Limited Co owns 208 shares for 0% of their portfolio. Renaissance Group Limited Liability has 120,893 shares. Condor Capital has 0.3% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 9,106 shares. Ardsley Advisory Ptnrs holds 2.4% or 106,000 shares. Moreover, Jpmorgan Chase And Com has 0.05% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Greenwood Assocs Llc holds 0.06% of its portfolio in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 1,732 shares. Jane Street Group Inc Ltd Liability Corp owns 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 1,628 shares.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Sarepta’s DMD Gene Therapy, Anika’s Flunked Trial, Eidos To Commence Trading” on June 20, 2018, also Nasdaq.com with their article: “Report: Exploring Fundamental Drivers Behind Mitel Networks, Celestica, CoreCivic, Inc., Jazz Pharmaceuticals, Open …” published on June 04, 2018, Nasdaq.com published: “3 Biotechs on the FDA’s Naughty List That Should Be on Investors’ Buy Lists” on May 22, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Seekingalpha.com and their article: “Key events next week – healthcare” published on June 01, 2018 as well as Prnewswire.com‘s news article titled: “Jazz Pharmaceuticals to Present at the Goldman Sachs Global Healthcare Conference” with publication date: June 05, 2018.

Reliance Steel & Aluminum Co. (NYSE:RS) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>